Protecting Students from MenB

A Partnership with Pfizer, Inc.

Published August 2018

Serogroup B meningococcal disease (MenB) is the leading cause of meningococcal disease among U.S. adolescents and young adults and accounts for approximately 60% of all meningococcal disease cases in persons 16 to 23 years of age in the United States. MenB is an uncommon but deadly disease that progresses rapidly and is often difficult to diagnose early enough to treat effectively. Despite appropriate medical treatment ~10% of people with MenB die and one in five survivors experience long-term physical and mental disabilities. College-age persons—adolescents and young adults—are uniquely susceptible to meningococcal disease due to inherent environmental and social risk factors such as close-quartered living and sharing behaviors.

ACHF, in partnership with Pfizer, has developed educational brochures for key stakeholders to bridge the gap of knowledge regarding MenB and MenB vaccines. These materials were developed specifically for college students and campus health professionals/administrators.

For Health Care Professionals

Developed in partnership with Pfizer, this brochure provides education to college health professionals/administrations around serogroup B meningococcal disease (MenB) and preventive vaccination to help provide adequate protection of college-age individuals.

The brochure includes information on the causes, symptoms, and spread of meningococcal disease; epidemiology of meningococcal disease among college students; recommendations from the CDC Advisory Committee on Immunization Practices and who should be vaccinated; and developing a pre-matriculation plan.

The brochure can be ordered as a free downloadable PDF through the ACHA Store.

ORDER NOW

For Students

ACHF, in partnership with Pfizer, developed a digital brochure to be shared with students to help educate them on the causes, symptoms, and spread of serogroup B meningococcal disease (MenB). The brochure also highlights prevention of MenB through vaccination and the rates of MenB compared to other serogroups. Available materials include a PDF version as well as images to be shared on a campus website or through social media accounts.

This brochure can be posted directly on your campus health center website as either an image or a PDF, or shared on social media platforms.

Materials include:

· A PDF for printing or posting as link on a website
·  An image for web posting (a PNG for posting as an image on a website)
·  Social media-optimized images (PNGs for sharing on social media sites)

Available as a free download.

ORDER NOW

References

¹Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.

²Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. https://www.cdc.gov-
/meningococcal/about/symptoms.html. Updated June 7, 2017.

³Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications
for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-191.

⁴Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J.
2013;32(1):e20-e25.

⁵Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics.
2009;123:e502-e509.

⁶Centers for Disease Control and Prevention. Meningococcal surveillance. Centers for Disease Control and Prevention website.
https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf

⁷Meyer S. Epidemiology of meningococcal disease among college students – United States, 2014-2016. ACIP. February 2018.
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-02/Mening-02-Meyer-508.pdf

⁸Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis.
2010;10(12):853-861.

⁹World Health Organization. http://www.who.int/mediacentre/factsheets/fs141/en/. Reviewed January 2018.

¹⁰Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ.
2006;332(7539):445-450.

¹¹Dwillow R and Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep.
2015;15(2):1-9.

¹²MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the
Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1176.